Search results
Results from the WOW.Com Content Network
Syngeneic lymphocytes were transferred from rodents heavily immunized against the tumor to inhibit growth of small established tumors, becoming the first example of ACT. [ 3 ] Description of T cell growth factor interleukin-2 (IL-2) in 1976 allowed T lymphocytes to be grown in vitro , often without loss of effector functions.
Even more interesting was the fact that both these cytokines were required for maximal tumor immunity, and that mice deficient in either showed greatly reduced antitumor immunity. IFN-γ null mice showed virtually no immunity, while IL-4 null mice showed a 50% reduction when compared to immunised wild type mice.
According to a 2015 review article, Lewis lung carcinoma is the only reproducable syngeneic lung cancer model, meaning that it is the only reproducible lung cancer model that utilizes a transplant that is immunologically compatible. Syngeneic models have proven to be useful in predicting clinical benefit of therapy in preclinical experiments.
The tumor microenvironment is a complex system of various tumor cells, stromal cells, and immune cells. [1] The tumor microenvironment is a complex ecosystem surrounding a tumor, composed of cancer cells, stromal tissue (including blood vessels, immune cells, fibroblasts and signaling molecules) and the extracellular matrix.
The next step in cancer immunoediting is the equilibrium phase, during which tumor cells that have escaped the elimination phase and have a non-immunogenic phenotype are selected for growth. Lymphocytes and IFN-gamma exert a selection pressure on tumor cells which are genetically unstable and rapidly mutating. Tumor cell variants which have ...
Tumor-associated immune cells in the tumor microenvironment (TME) of breast cancer models. Cancer immunology (immuno-oncology) is an interdisciplinary branch of biology and a sub-discipline of immunology that is concerned with understanding the role of the immune system in the progression and development of cancer; the most well known application is cancer immunotherapy, which utilises the ...
This process is necessary for immunity against most tumors [2] and against viruses that infect dendritic cells and sabotage their presentation of virus antigens. [3] [4] Cross presentation is also required for the induction of cytotoxic immunity by vaccination with protein antigens, for example, tumour vaccination. [5]
It has long been debated whether cancer cells were bearing "tumor-specific" antigens, absent from normal cells, which could, in principle, cause the elimination of the tumor by the immune system. It is now proven that tumor-specific antigens exist and that patients mount spontaneous T cell responses against such antigens. Unfortunately, it is ...